Sales of the R20 neurostimulator have already begun in Canada, and Axonics said in this week’s announcement that it’s aiming to expand that rollout southward to the U.S. within the next few months.

Axonics' R20 system is designed to be implanted for at least 20 years. It needs to be recharged for only one hour every six to 10 months—essentially, just twice a year—compared to previous generations ...

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical ...

But I guess I wanted to start on Bulkamid first. I know you've talked about the product in the past being sort of catnip for the physicians and the ability to pull across different SNM implants. And ...

Medtronic is going after Axonics once again, this time with accusations that its competitor in sacral neuromodulation is illegally using Medtronic’s MRI compatibility technology. The accusations come ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first ...